StockData
Parabilis Medicines, Inc. logo

Parabilis Medicines, Inc. (PBLS) stock

PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$28.47+0.22 (+0.78%)

Close on Nov 18, 2026Market cap $3.52BP/E –Yield –

Earnings

Parabilis Medicines's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2026
$2.10M
EPS, Q3 FY2026
-$0.36
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Parabilis Medicines's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open$2.10M–-$0.36Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open$148.00K–-$2.32Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Parabilis Medicines has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Parabilis Medicines puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Parabilis Medicines filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?